Consolidated Entities - Entasis Therapeutics Holdings, Inc. (Details) $ / shares in Units, $ in Thousands		3 Months Ended				6 Months Ended
	Feb. 17, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) Director	Jun. 30, 2021 USD ($) $ / shares	Dec. 31, 2021 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Total debt		$ 549,704				$ 549,704		$ 433,484
Noncontrolling interest		177,125				177,125		$ 111,192
Net income attributable to noncontrolling interest		20,432	$ 21,898			42,517	$ 37,470
Remeasurement loss						7,700
Net loss attributable to Innoviva stockholders		939	88,948			$ 16,712	183,071
Entasis Therapeutics Holdings Inc
Subsidiary or Equity Method Investee [Line Items]
Number of investee's board members which may be designated by the Company | Director						2
Noncontrolling interest	$ 38,500
Increase/Decrease in fair value related to equity method investments			$ 64,700			$ (7,800)	53,200
Decrease for acquisition related costs							$ 100
Increase for acquisition related costs						100
Equity investment ownership percentage	59.90%
Net loss attributable to Innoviva stockholders		$ 11,700				$ 16,300
Entasis Therapeutics Holdings Inc | Securities Purchase Agreement | Convertible Promissory Note
Subsidiary or Equity Method Investee [Line Items]
Total debt	$ 15,000
Debt instrument maturity date	Aug. 18, 2022
Debt Instrument, annual interest rate	0.59%
Conversion price (dollars per share) | $ / shares	$ 1.48
Entasis Therapeutics Holdings Inc | Common stock
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares				4,672,897	14,000,000
Fair value of equity securities	$ 64,500
Entasis Therapeutics Holdings Inc | Common stock | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares			10,000,000
Entasis Therapeutics Holdings Inc | Warrants
Subsidiary or Equity Method Investee [Line Items]
Number of warrants purchased under the securities purchase agreement | shares				4,672,897	14,000,000
Fair value of equity securities	$ 31,400
Entasis Therapeutics Holdings Inc | Warrants | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Number of shares to be purchased under the securities purchase agreement | shares			10,000,000
Entasis Therapeutics Holdings Inc | Common stock and warrants
Subsidiary or Equity Method Investee [Line Items]
Payments to acquire equity securities				$ 12,500	$ 35,000
Entasis Therapeutics Holdings Inc | Common stock and warrants | Innoviva Strategic Opportunities, LLC
Subsidiary or Equity Method Investee [Line Items]
Payments to acquire equity securities			$ 20,000
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2021
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares			$ 2.00				$ 2.00
Term of warrants		5 years				5 years
Entasis Therapeutics Holdings Inc | Warrants acquired in third quarter of 2020
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares				$ 2.675
Term of warrants		5 years				5 years
Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2020
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrants | $ / shares					$ 2.50
Term of warrants		5 years				5 years